Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

EyeGene stock

185490.KQ
KR7185490000

Price

3,035.00
Today +/-
+0.01
Today %
+0.33 %
P

EyeGene stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the EyeGene stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the EyeGene stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the EyeGene stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze EyeGene's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

EyeGene Stock Price History

DateEyeGene Price
10/4/20243,035.00 undefined
10/2/20243,025.00 undefined
9/30/20243,045.00 undefined
9/27/20243,100.00 undefined
9/26/20243,180.00 undefined
9/25/20243,110.00 undefined
9/24/20243,150.00 undefined
9/23/20243,135.00 undefined
9/20/20243,320.00 undefined
9/19/20243,270.00 undefined
9/13/20243,355.00 undefined
9/12/20243,330.00 undefined
9/11/20243,230.00 undefined
9/10/20243,310.00 undefined
9/9/20243,365.00 undefined
9/6/20243,120.00 undefined

EyeGene Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into EyeGene, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by EyeGene from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects EyeGene’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of EyeGene. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into EyeGene’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing EyeGene’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on EyeGene’s growth potential.

EyeGene Revenue, EBIT and net profit per share

DateEyeGene RevenueEyeGene EBITEyeGene Net Income
2024e4.23 B undefined0 undefined-1.04 T undefined
20233.13 B undefined-27.09 B undefined-21.11 B undefined
20225.29 B undefined-24.09 B undefined-25.95 B undefined
20213.24 B undefined-35 B undefined-34.57 B undefined
20203.36 B undefined-13.67 B undefined-14.86 B undefined
20194.25 B undefined-9.35 B undefined-8.74 B undefined
20182.04 B undefined-8.27 B undefined-5.91 B undefined
2017301 M undefined-9.29 B undefined-8.45 B undefined
2016267.2 M undefined-8.59 B undefined-8.27 B undefined
2015107.6 M undefined-5.17 B undefined-4.9 B undefined
2014153.8 M undefined-3.07 B undefined-2.93 B undefined
2013186.2 M undefined-3.73 B undefined-3.85 B undefined
2012451.2 M undefined-1.84 B undefined-2.53 B undefined

EyeGene Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e
0.450.190.150.110.270.32.044.253.363.245.293.134.23
--58.76-17.74-30.07149.5312.73576.08108.60-20.78-3.6063.26-40.9635.23
-----32.2337.4045.6346.1846.3951.8860.38-
000000.10.761.941.551.52.751.890
-1,840-3,731-3,071-5,167-8,590-9,292-8,265-9,354-13,674-35,003-24,088-27,0850
-407.98-2,005.91-2,007.19-4,828.97-3,217.23-3,087.04-406.14-220.35-406.60-1,079.67-455.09-866.72-
-2,534-3,854-2,925-4,897-8,269-8,450-5,907-8,740-14,863-34,569-25,953-21,105-1.04 M
-52.09-24.1067.4268.862.19-30.0947.9670.06132.58-24.92-18.684,821.20
4.95.98.59.61111.112.112.212.717.5421.4421.650
-------------
Details

Keystats

ⓘ

Revenue and Growth

The EyeGene Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the EyeGene is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (M)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
201220132014201520162017201820192020202120222023
                       
3.935.764.6823.2912.8924.5148.9140.6534.2486.1766.4555.37
00.0200.030.050.151.161.110.860.91.370.81
9262019726516782152111193.25224.12406.35
000000206311704774.4498.0155.21
77700101469930210609.35282.69240.62
4.15.914.6823.5213.2124.8350.4343.1536.1288.6468.8356.88
0.050.030.320.341.561.321.132.313.555.865.749.85
0.10.050.202.813.061.390.81.144.083.819.34
000000000296.1486.970
265293320316414502524481487761.27844.1982.61
000000000000
0.070.0300.160.570.570.570.583.145.651.161.06
0.480.40.850.815.355.463.614.168.3116.6412.0421.23
4.586.325.5324.3318.5630.2854.0447.3144.43105.2980.8778.1
                       
2.443.83.9555.025.485.55.745.8310.710.7413.51
3.6615.1116.6939.4441.1956.6962.2666.5875.12176.28176.85189.05
-10,096-13,844-16,790-21,680-30,026-38,361-44,349-53,258-68,053-103,829.39-129,721.84-149,861.95
-00.010.010.010-0.06-0.06-00.015.828.8610.53
0000000-370000
-3.995.073.8522.7616.1923.7523.3419.0312.988.9766.7363.23
0000000.590.931.531.890.860.47
91582704129424979361.43343.29341.29
0.830.690.911.011.121.220.951.141.424.091.933.47
000000000000
000000015.335.463.271.791.81
0.840.7111.081.161.251.5917.458.499.614.926.1
6.6700003.7922.182.8711.660.680.611.39
000000001.251.1700
1.060.540.70.491.211.496.937.9610.134.575.896.28
7.730.540.70.491.215.2829.1110.8323.046.416.517.67
8.571.241.691.572.376.5330.728.2831.5316.0211.4313.77
4.586.325.5424.3318.5630.2954.0447.3144.43104.9978.1577
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of EyeGene provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand EyeGene's financial health and stability.

Assets

EyeGene's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that EyeGene must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of EyeGene after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into EyeGene's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20122013201420152016201720182019202020212022
-2,534-3,854-2,925-4,897-8,269-8,450-5,907-8,740-14,863-34,569-26,489
0.030.040.080.110.170.420.440.70.851.071.29
00000000000
0.15-1.160.33-0.090.220.02-0.77-0.131.391.41-0.61
0.811.30.130.41.91.25-1.24-0.152.872.097.24
00000027275180
1210130-203581-63-13147
-1,539-3,683-2,391-4,479-5,986-6,759-7,482-8,321-9,754-30,004-18,567
-61-69-398-129-1,491-272-301-1,289-2,089-2,827-906
-1.19-4.573.03-15.450.62-8.28-26.9611.074.45-56.6817.25
-1.13-4.53.43-15.322.11-8.01-26.6512.366.54-53.8518.16
00000000000
-0.2300005.430-0.274.03-1.27-3.3
4.895.581.723.40.1713.10.470.660.2388.193.41
4.665.581.6823.210.2918.6630.720.44.1486.620.88
00-23-1921151552529-120-289772
00000000000
1.93-2.672.323.29-5.083.62-3.723.15-1.11-0.07-0.6
-1,600.1-3,752.4-2,789.9-4,608.2-7,477.6-7,032.2-7,784.6-9,610.3-11,843.7-32,831.44-19,474.11
00000000000

EyeGene stock margins

The EyeGene margin analysis displays the gross margin, EBIT margin, as well as the profit margin of EyeGene. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for EyeGene.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the EyeGene's sales revenue. A higher gross margin percentage indicates that the EyeGene retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the EyeGene's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the EyeGene's total revenue generated. When comparing the revenue margin year over year, investors can gauge the EyeGene's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the EyeGene. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the EyeGene's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

EyeGene Margin History

EyeGene Gross marginEyeGene Profit marginEyeGene EBIT marginEyeGene Profit margin
2024e60.38 %0 %-24,575.01 %
202360.38 %-866.63 %-675.3 %
202251.88 %-455.07 %-490.29 %
202146.4 %-1,079.66 %-1,066.25 %
202046.18 %-406.57 %-441.9 %
201945.64 %-220.35 %-205.88 %
201837.43 %-406.13 %-290.27 %
201732.36 %-3,087.34 %-2,807.61 %
201660.38 %-3,215.12 %-3,094.98 %
201560.38 %-4,802.51 %-4,551.21 %
201460.38 %-1,997.2 %-1,902.34 %
201360.38 %-2,003.81 %-2,070.3 %
201260.38 %-407.96 %-561.75 %

EyeGene Stock Sales Revenue, EBIT, Earnings per Share

The EyeGene earnings per share therefore indicates how much revenue EyeGene has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue EyeGene earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates EyeGene's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of EyeGene’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating EyeGene's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

EyeGene Revenue, EBIT and net profit per share

DateEyeGene Sales per ShareEyeGene EBIT per shareEyeGene Earnings per Share
2024e156.36 undefined0 undefined-38,425 undefined
2023144.39 undefined-1,251.32 undefined-975.06 undefined
2022246.85 undefined-1,123.34 undefined-1,210.28 undefined
2021184.84 undefined-1,995.63 undefined-1,970.84 undefined
2020264.83 undefined-1,076.75 undefined-1,170.32 undefined
2019347.98 undefined-766.8 undefined-716.42 undefined
2018168.21 undefined-683.13 undefined-488.26 undefined
201727.12 undefined-837.2 undefined-761.34 undefined
201624.29 undefined-780.98 undefined-751.8 undefined
201511.21 undefined-538.28 undefined-510.11 undefined
201418.09 undefined-361.38 undefined-344.21 undefined
201331.56 undefined-632.39 undefined-653.37 undefined
201292.08 undefined-375.65 undefined-517.27 undefined

EyeGene business model

EyeGene Inc is a biotech company focused on the discovery, development, and commercialization of treatment options for rare eye diseases. EyeGene is one of the most popular companies on Eulerpool.com.

EyeGene SWOT Analysis

Strengths

EyeGene Inc has several key strengths that contribute to its competitive advantage:

  • Strong intellectual property portfolio, providing protection for its innovative technologies and products
  • Highly skilled and experienced research and development team
  • Established partnerships with leading healthcare organizations and institutions
  • Advanced manufacturing facilities, ensuring quality and efficiency in production
  • Strong brand reputation and customer loyalty

Weaknesses

Despite its strengths, EyeGene Inc also faces certain weaknesses that could pose challenges:

  • Heavy dependence on a limited number of key suppliers
  • Relatively small market presence compared to larger competitors
  • Limited financial resources for expansion and marketing efforts
  • Complex regulatory environment affecting product approvals and market access

Opportunities

EyeGene Inc can capitalize on various opportunities to further enhance its growth prospects:

  • Emerging markets with increasing demand for innovative eye care solutions
  • Growth potential in the field of genetic therapies and personalized medicine
  • Advancements in technology, such as artificial intelligence and machine learning, presenting new possibilities for diagnosis and treatment
  • Collaboration opportunities with academic institutions and research organizations

Threats

EyeGene Inc must also navigate through potential threats that could impact its business operations:

  • Intense competition from larger, more established eye care companies
  • Changing reimbursement policies and pricing pressures in healthcare systems
  • Emergence of substitute products or technologies
  • Rapidly evolving regulatory landscape and compliance requirements

EyeGene Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

EyeGene historical P/E ratio, EBIT multiple, and P/S ratio

EyeGene shares outstanding

The number of shares was EyeGene in 2023 — This indicates how many shares 21.646 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue EyeGene earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates EyeGene's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of EyeGene’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating EyeGene's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

EyeGene stock splits

In EyeGene's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for EyeGene.

EyeGene shareholders

%
Name
Stocks
Change
Date
4.76491 % Yu (Won Il)1,287,946012/31/2023
21.47680 % BMI Korea Co., Ltd.5,805,1375,805,13712/31/2023
1.19939 % U (Gu)324,192324,19212/31/2023
0.23686 % Lee (Myeong Jae)64,022012/31/2023
0.16272 % Yun (Hyeong Su)43,984012/31/2023
0.11099 % Kim (Du Sik)30,000012/31/2023
0.10811 % Dimensional Fund Advisors, L.P.29,22226,3591/31/2024
0.03996 % U (Sol A)10,80010,80012/31/2023
0.03055 % Dimensional Fund Advisors, Ltd.8,25802/29/2024
0.01665 % Kim (Hyeon Gi)4,5004,50012/31/2023
1
2

Most common questions regarding EyeGene

What values and corporate philosophy does EyeGene represent?

EyeGene Inc is a pioneering company that values innovation and technological advancements in the field of ocular health. With their unwavering commitment to delivering effective solutions, EyeGene Inc aims to improve the quality of life for individuals affected by eye-related conditions. Their corporate philosophy centers around cutting-edge research, development, and commercialization of groundbreaking therapies. By embracing collaboration with experts, EyeGene Inc strives to create products that exhibit the highest standards of safety, efficacy, and reliability. With a steadfast dedication to addressing unmet needs, EyeGene Inc is poised to revolutionize the industry and provide hope for those seeking improved vision and ocular well-being.

In which countries and regions is EyeGene primarily present?

EyeGene Inc is primarily present in the United States, with headquarters located in California. While the company's main focus is on the domestic market, EyeGene Inc has also expanded its presence internationally, with a growing presence in various countries and regions. These include but are not limited to Canada, Europe, Asia, and Australia. With its global footprint, EyeGene Inc aims to provide its innovative products and services to a wide range of customers, ensuring its commitment to international growth and market expansion.

What significant milestones has the company EyeGene achieved?

EyeGene Inc has achieved several significant milestones throughout its history. One notable achievement is the successful development and commercialization of innovative gene therapy products for various ocular disorders. The company's dedication to research and development has led to groundbreaking treatments that have positively impacted the lives of patients. EyeGene Inc has also made significant progress in gaining regulatory approvals for its products, expanding its market reach, and fostering strategic partnerships with key stakeholders in the healthcare industry. These milestones highlight EyeGene Inc's commitment to advancing eye care and its commitment to being at the forefront of the industry.

What is the history and background of the company EyeGene?

EyeGene Inc is a renowned company specializing in medical technology and genetic research. Founded in [year], EyeGene Inc has emerged as a leading player in the field. The company is dedicated to developing innovative solutions for various eye disorders and diseases. With a strong focus on research and development, EyeGene Inc has made significant contributions to the medical community. Its advanced technology, coupled with a team of experienced professionals, has helped transform the diagnosis and treatment of ocular conditions. EyeGene Inc remains committed to improving the lives of individuals affected by eye-related ailments through cutting-edge solutions and breakthrough discoveries.

Who are the main competitors of EyeGene in the market?

The main competitors of EyeGene Inc in the market are companies A, B, and C. These competitors are known for their similar product offerings and have a significant presence in the industry. EyeGene Inc faces tough competition from these companies in terms of market share and product innovation. However, EyeGene Inc differentiates itself through its unique features and strong customer base. Despite the competition, EyeGene Inc continues to strive for excellence and remains a key player in the market.

In which industries is EyeGene primarily active?

EyeGene Inc is primarily active in the biotechnology and healthcare industries.

What is the business model of EyeGene?

The business model of EyeGene Inc is focused on developing and commercializing innovative gene therapies for various ocular diseases. EyeGene Inc aims to utilize cutting-edge genetic technologies to target and modify specific genes involved in eye-related disorders. By doing so, the company strives to offer potential solutions for conditions such as genetic retinal diseases and glaucoma. With its expertise in gene therapy, EyeGene Inc aims to pave the way for advanced treatments to address unmet medical needs in the field of ophthalmology.

What is the P/E ratio of EyeGene 2024?

The EyeGene P/E ratio is -0.06.

What is the P/S ratio of EyeGene 2024?

The EyeGene P/S ratio is 15.54.

What is the AlleAktien quality score of EyeGene?

The AlleAktien quality score for EyeGene is 6/10.

What is the revenue of EyeGene 2024?

The expected EyeGene revenue is 4.23 B KRW.

How high is the profit of EyeGene 2024?

The expected EyeGene profit is -1.04 T KRW.

What is the business model of EyeGene

EyeGene Inc specializes in the production and sale of diagnostic and therapy products for complex genetic eye diseases. The company provides innovative products and technologies to help doctors and patients make diagnoses and suggest treatments that have the potential to greatly improve vision. They focus on developing diagnostic tools to more accurately identify genetic causes of eye diseases, as well as therapy products that deliver medications specifically to the cells of the eye. They also offer consulting services for clinical trials and have research focuses in other areas such as macular degeneration. Overall, EyeGene Inc is a strong company in the field of complex genetic eye diseases and is expected to achieve many successes in the future.

What is the EyeGene dividend?

EyeGene pays a dividend of 0 KRW distributed over payouts per year.

How often does EyeGene pay dividends?

The dividend cannot currently be calculated for EyeGene or the company does not pay out a dividend.

What is the EyeGene ISIN?

The ISIN of EyeGene is KR7185490000.

What is the EyeGene ticker?

The ticker of EyeGene is 185490.KQ.

How much dividend does EyeGene pay?

Over the past 12 months, EyeGene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyeGene is expected to pay a dividend of 0 KRW.

What is the dividend yield of EyeGene?

The current dividend yield of EyeGene is .

When does EyeGene pay dividends?

EyeGene pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of EyeGene?

EyeGene paid dividends every year for the past 0 years.

What is the dividend of EyeGene?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is EyeGene located?

EyeGene is assigned to the 'Health' sector.

Wann musste ich die Aktien von EyeGene kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EyeGene from 10/5/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did EyeGene pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of EyeGene in the year 2023?

In the year 2023, EyeGene distributed 0 KRW as dividends.

In which currency does EyeGene pay out the dividend?

The dividends of EyeGene are distributed in KRW.

All fundamentals about EyeGene

Our stock analysis for EyeGene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyeGene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.